Welcome to our dedicated page for QT IMAGING HOLDINGS SEC filings (Ticker: QTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
QT Imaging Holdings, Inc. (QTI) files SEC reports as a Nasdaq-listed medical device company focused on body imaging systems that use low-frequency sound waves. Its filings are useful for following how the company describes the commercialization, regulation and financing of its Breast Acoustic CT imaging platform.
Quarterly reports on Form 10-Q provide financial statements, accounting notes and management disclosures. For QTI, these reports have included items tied to breast scanning system placements, revenue expectations used in earnout liability valuation, warrants, reverse stock split adjustments and share information. Annual reports on Form 10-K, when filed, provide broader business, risk and financial disclosures.
Current reports on Form 8-K are especially relevant for QTI because they document material events between periodic reports. Recent 8-K categories include earnings releases, shareholder communications, financing agreements, stockholder meeting results, executive compensation actions and equity award grants. These filings help show how QT Imaging communicates operational updates, governance actions and capital markets activity.
The company's proxy statements describe matters submitted to stockholders, including director elections, auditor ratification and equity incentive plan proposals. For a medical device issuer such as QTI, SEC filings help investors evaluate the link between product commercialization, regulatory disclosures, governance decisions and the capital structure supporting the company's imaging technology business.
Dinu Raluca reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings, Inc. reported that Chief Executive Officer Raluca Dinu received equity awards of common stock as compensation. On March 20, 2026, she was granted 3,500, 500,000, and 16,000 shares of common stock at a price of $0.00 per share under the company’s equity plan.
After these awards, the filing shows she directly owns 908,845 common shares. Footnotes explain these are restricted stock units with vesting schedules running from May 15, 2026 through dates as late as February 15, 2030 or May 15, 2029, with full acceleration upon a qualifying Change of Control.
Katz Avi S reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings, Inc. chairman Avi S. Katz received a grant of 3,500 shares of common stock on March 20, 2026 as a stock award, at a stated price of $0.00 per share. Following this grant, he directly holds 416,952 common shares.
The award is structured as restricted stock units. Subject to his continued service, 25% of the RSUs will vest on each of May 15, 2026, August 15, 2026, November 15, 2026, and February 15, 2027. All RSUs will vest immediately if the company undergoes a Change of Control under its 2024 Equity Incentive Plan.
DICKSON DANIEL H reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings, Inc. director Daniel H. Dickson reported receiving a grant of 3,500 shares of Common Stock, awarded as restricted stock units at a stated price of $0.0000 per share. Following the award, he directly holds 32,039 Common shares.
According to the vesting terms, subject to his continued service to the company, 25% of the RSUs will vest on each of May 15, 2026, August 15, 2026, November 15, 2026, and February 15, 2027. All RSUs will vest immediately upon a qualifying Change of Control under the company’s 2024 Equity Incentive Plan. The filing also notes that the reported beneficial ownership reflects a 3-for-1 reverse stock split effective October 23, 2025.
QT Imaging Holdings, Inc. released an investor presentation highlighting rapid commercial growth for its breast imaging platform and updated financials. Revenue reached $18.9 million in 2025, up from $4.9 million in 2024, driven by shipment of 40 QT Breast Acoustic CT scanners under distribution agreements.
Q4 2025 revenue was $8.3 million, an 877% year-over-year increase, with 38% gross margin and a net loss of $1.4 million. Adjusted EBITDA improved to $(0.4) million from $(1.9) million a year earlier. The company ended 2025 with $10.5 million in cash after an oversubscribed $18.2 million private placement and new debt financing, and it expects approximately $39 million of revenue in 2026, including initial SaaS cloud platform contributions.
QT Imaging Holdings, Inc. reported preliminary unaudited results showing record revenue of $8.3 million in Q4 2025 and $18.9 million for full-year 2025, exceeding its $18 million outlook. Q4 revenue rose 877% year over year and 97% sequentially, driven by shipment of 17 Breast Acoustic CT™ scanners.
For 2025, revenue grew 288% versus 2024, with 40 scanners shipped. Gross margin was 45% for the year and 38% in Q4. Despite this growth, the company recorded a 2025 net loss of $21.1 million, influenced by $8.8 million of other expense tied to term loan issuance, note extinguishments and fair value changes.
Non-GAAP Adjusted EBITDA improved to $(3.5) million from $(7.4) million in 2024, while net cash used in operating activities narrowed to $9.0 million. Cash, restricted cash and equivalents reached $10.5 million at year-end 2025 after an $18.2 million private placement and new debt financings. The company relisted on Nasdaq and is pivoting from pure hardware to a SaaS and biomarker-driven imaging platform, and it projects 2026 revenue of about $39 million, including initial SaaS Cloud Platform contributions.
Alyeska Investment Group and related parties reported a sizable position in QT Imaging Holdings, Inc. common stock. As of December 31, 2025, they beneficially owned 1,178,317 shares, representing 9.99% of the company’s common stock.
The position is held through 670,683 common PIPE shares, pre-funded warrants for 440,427 shares, and warrants for 1,111,111 shares. These warrants are subject to a 9.9% beneficial ownership limitation, meaning they can only be exercised to a level where Alyeska would hold up to 9.9% of QT Imaging’s outstanding common stock after exercise.
The ownership figures are based on 11,902,198 shares outstanding, as disclosed in QT Imaging’s prospectus dated December 31, 2025. Alyeska certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
QT Imaging Holdings, Inc. received an updated ownership report from investment firm Lynrock Lake entities and Cynthia Paul. As of December 31, 2025, they beneficially owned 1,154,586 shares of QT Imaging common stock, representing 9.7% of the outstanding shares based on 11,902,198 shares reported outstanding.
The shares are directly held by Lynrock Lake Master Fund LP, with voting and investment power delegated to Lynrock Lake LP as investment manager and influenced by Cynthia Paul through her roles at the related entities. Lynrock Lake Master also holds warrants that are currently restricted by approximately 4.9% beneficial ownership limits. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of QT Imaging.
QT Imaging Holdings, Inc. filed an 8-K to furnish its audited consolidated financial statements for 2024 and 2023, updated to reflect a 3‑for‑1 reverse stock split effective October 23, 2025. The audit received an unqualified opinion under U.S. GAAP.
For 2024, revenue rose sharply to $4.88 million from $0.04 million in 2023, driven mainly by product sales. Despite this, the company reported a net loss of $8.98 million and a net loss attributable to common stockholders of $14.17 million, or $(2.13) per share. At year-end 2024, QT Imaging held $1.19 million in cash and restricted cash, total assets of $6.09 million, total liabilities of $15.62 million, and a stockholders’ deficit of $(9.54 million).
The notes describe the March 4, 2024 business combination with GigCapital5, significant use of convertible and structured financing, concentration of revenue in a few customers, and subsequent capital arrangements and distribution agreements that management believes will fund the operating plan for at least the next 12 months.
Jay Walter Jennings, identified as a Director and Chief Financial Officer of QT Imaging Holdings (ticker QTI), filed an Initial Statement of Beneficial Ownership on 09/02/2025. The filing discloses a stock option covering 325,000 shares of common stock with an exercise price of $1.90 and an indicated expiration date of 09/02/2035. The option vests one-third on August 15, 2026 with the remaining two-thirds vesting in eight equal quarterly installments and fully vesting on August 15, 2028, subject to continued service.
Anastas Budagov, identified as Chief Financial Officer of QT Imaging Holdings, Inc. (QTIH), filed a Form 4 stating his insider status terminated as of August 29, 2025. The filing shows no reported non-derivative or derivative transactions on the form and notes the reporting person is no longer subject to Section 16 obligations following that termination.